$2.25
-0.10[-4.26%]
At close: Apr 25
$2.25
0[0.00%]
After Hours: 4:20PM EDT
BioAtla
(NASDAQ:BCAB)BioAtla Stock (NASDAQ:BCAB), Analyst Ratings, Price Targets, Predictions
BioAtla Inc has a consensus price target of $21.75, established from looking at the 27 latest analyst ratings. The last 3 analyst ratings were released from JMP Securities, HC Wainwright & Co., and JMP Securities on March 28, 2024, March 27, 2024, and December 5, 2023. With an average price target of $10.33 between JMP Securities, HC Wainwright & Co., and JMP Securities, there's an implied 359.26% upside for BioAtla Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
JMP Securities
HC Wainwright & Co.
JP Morgan
EF Hutton
BTIG
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for BioAtla
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 03/28/2024 | BCAB | Buy Now | BioAtla | $2.25 | 433.33% | JMP Securities | Reni Benjamin | → $12 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 03/27/2024 | BCAB | Buy Now | BioAtla | $2.25 | 211.11% | HC Wainwright & Co. | Arthur He | $10 → $7 | Maintains | Buy | Get Alert |
| 12/05/2023 | BCAB | Buy Now | BioAtla | $2.25 | 433.33% | JMP Securities | Reni Benjamin | → $12 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 11/08/2023 | BCAB | Buy Now | BioAtla | $2.25 | 344.44% | HC Wainwright & Co. | Arthur He | $17 → $10 | Maintains | Buy | Get Alert |
| 09/25/2023 | BCAB | Buy Now | BioAtla | $2.25 | 522.22% | JP Morgan | Brian Cheng | $17 → $14 | Maintains | Overweight | Get Alert |
| 08/02/2023 | BCAB | Buy Now | BioAtla | $2.25 | 655.56% | JP Morgan | Brian Cheng | $19 → $17 | Maintains | Overweight | Get Alert |
| 08/02/2023 | BCAB | Buy Now | BioAtla | $2.25 | 433.33% | JMP Securities | Reni Benjamin | → $12 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 08/02/2023 | BCAB | Buy Now | BioAtla | $2.25 | 1011.11% | EF Hutton | Tony Butler | → $25 | Reiterates | Buy → Buy | Get Alert |
| 08/02/2023 | BCAB | Buy Now | BioAtla | $2.25 | 655.56% | HC Wainwright & Co. | Arthur He | → $17 | Reiterates | Buy → Buy | Get Alert |
| 05/15/2023 | BCAB | Buy Now | BioAtla | $2.25 | 433.33% | JMP Securities | Reni Benjamin | $12 → $12 | Reiterates | Outperform → Outperform | Get Alert |
| 05/15/2023 | BCAB | Buy Now | BioAtla | $2.25 | 655.56% | HC Wainwright & Co. | Arthur He | → $17 | Reiterates | Buy → Buy | Get Alert |
| 05/12/2023 | BCAB | Buy Now | BioAtla | $2.25 | 1011.11% | EF Hutton | Tony Butler | → $25 | Reiterates | Buy → Buy | Get Alert |
| 04/17/2023 | BCAB | Buy Now | BioAtla | $2.25 | 1011.11% | EF Hutton | Tony Butler | → $25 | Maintains | Buy | Get Alert |
| 04/03/2023 | BCAB | Buy Now | BioAtla | $2.25 | 744.44% | JP Morgan | Brian Cheng | $23 → $19 | Maintains | Overweight | Get Alert |
| 03/28/2023 | BCAB | Buy Now | BioAtla | $2.25 | 477.78% | BTIG | Thomas Shrader | $68 → $13 | Maintains | Buy | Get Alert |
| 03/27/2023 | BCAB | Buy Now | BioAtla | $2.25 | 433.33% | JMP Securities | Reni Benjamin | $17 → $12 | Maintains | Outperform | Get Alert |
| 03/24/2023 | BCAB | Buy Now | BioAtla | $2.25 | 255.56% | Credit Suisse | Tiago Fauth | → $8 | Reiterates | → Neutral | Get Alert |
| 03/24/2023 | BCAB | Buy Now | BioAtla | $2.25 | 1011.11% | EF Hutton | Tony Butler | → $25 | Reiterates | → Buy | Get Alert |
| 03/24/2023 | BCAB | Buy Now | BioAtla | $2.25 | 655.56% | HC Wainwright & Co. | Arthur He | $20 → $17 | Maintains | Buy | Get Alert |
FAQ
What is the target price for BioAtla (BCAB)?
The latest price target for BioAtla (NASDAQ: BCAB) was reported by JMP Securities on March 28, 2024. The analyst firm set a price target for $12.00 expecting BCAB to rise to within 12 months (a possible 433.33% upside). 12 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for BioAtla (BCAB)?
The latest analyst rating for BioAtla (NASDAQ: BCAB) was provided by JMP Securities, and BioAtla reiterated their market outperform rating.
When was the last upgrade for BioAtla (BCAB)?
There is no last upgrade for BioAtla.
When was the last downgrade for BioAtla (BCAB)?
The last downgrade for BioAtla Inc happened on May 5, 2022 when Credit Suisse changed their price target from $35 to $5 for BioAtla Inc.
When is the next analyst rating going to be posted or updated for BioAtla (BCAB)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of BioAtla, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for BioAtla was filed on March 28, 2024 so you should expect the next rating to be made available sometime around March 28, 2025.
Is the Analyst Rating BioAtla (BCAB) correct?
While ratings are subjective and will change, the latest BioAtla (BCAB) rating was a reiterated with a price target of $0.00 to $12.00. The current price BioAtla (BCAB) is trading at is $2.25, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.